...
机译:患者报告的患者患者患者患者1/2剂量 - 升级研究中患有Durvalumab治疗的局部晚期/转移性尿路上皮癌1108
Section of Hematology/OncologyUniversity of ChicagoChicago Illinois;
Sarah Cannon Research InstituteLondon United Kingdom;
Princess Margaret Cancer CentreToronto Ontario Canada;
Ottawa HospitalOttawa Ontario Canada;
David Geffen School of MedicineUniversity of CaliforniaLos Angeles California;
Virginia Cancer SpecialistsFairfax Virginia;
Moffitt Cancer CenterTampa Florida;
HonorHealth Research InstituteScottsdale Arizona;
AstraZenecaGaithersburg Maryland;
AstraZenecaGaithersburg Maryland;
AstraZenecaGaithersburg Maryland;
AstraZenecaGaithersburg Maryland;
MedImmuneGaithersburg Maryland;
MedImmuneGaithersburg Maryland;
MedImmuneGaithersburg Maryland;
MedImmuneGaithersburg Maryland;
University of California San Francisco Medical CenterSan Francisco California;
biomarkers; durvalumab; health‐related quality of life; inflammation; patient‐reported outcome measures; tumor; urothelial carcinoma;
机译:患者报告的患者患者患者患者1/2剂量 - 升级研究中患有Durvalumab治疗的局部晚期/转移性尿路上皮癌1108
机译:尿路上皮局部晚期或转移性移行细胞癌患者依维莫司的II期研究:临床活性,分子反应和生物标志物
机译:与患者报告的生活质量结果的规范语音和吞咽和吞咽和吞咽与吞咽性的数据的关联:来自HPV相关的,局部晚期口咽癌的剂量去升级化学校长的II期试验结果
机译:CCND1作为局部晚期头颈部鳞状细胞癌患者新辅助化疗的预测生物标志物
机译:长春新碱,伊非替康,替莫唑胺和贝伐单抗(VIT-B)逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
机译:Ib剂量递增研究对Cobimetinib和Duligotuzumab在先前已治疗的局部晚期或转移性KRAS突变癌症患者中的安全性耐受性和药代动力学
机译:用Durvalumab在1/2剂量升级研究中治疗局部晚期/转移性尿路上皮癌患者患者报告的结果和炎症生物标志物1108